StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Q1-2021 ER Thoughts ..

<< Previous

Bullboard Posts

Next >>

Comment by johnny007on May 17, 2021 8:31am

146 Views

Post# 33212838

RE:Q1-2021 ER Thoughts ..

A New Beginning, I read on the 1st slide.
In this case I like to hear them explaining how it shall be financed incl. merger/acquisition.

Also still waiting on the CoC financials!

OK: 5.5M loss are just paper losses, so the adjusted loss is around 1.7M (not 7.3M).

Still .. its 2M burn a qtr for StageZero, how much for Coc?
Then 6.2M current liabilities must be paid next 12 month, most sooner.

Phew ..

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages